Tags : HER2-Mutant

AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki)

Shots: The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer, prior treated with 2L standard therapies. Results: ORR (45.3%); DCR (83.0%); PFS (6.9mos.); subgroup patients including patients with treated with a prior anti-HER2 regimen, ORR (43.8%) with a median treatment duration of 4.8mos. […]Read More

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) Receive the US

Shots: The US FDA’s BT designation is based on an ongoing P-II DESTINY-Lung01 study assessing Enhertu in 170 patients with HER2 mutant or HER2 overexpressing unresectable and m-nsq. NSCLC, progressed after one or more systemic therapies including CT, molecular targeted therapy or immunotherapy and data from P-I study, published in Cancer Discovery The overall safety […]Read More